Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I Hope Karma gets there first as the SEC seems pretty toothless and controlled by people who provide his paycheck.
Most wanted headline: Citadel files for bankruptcy - on thestreet.com.
I believe all longs hope that LP rejects any settlement and goes for discovery. LP's mantra: Go Big or Go Home
Yes. One of the oldest FUDS in the fudster toolbox that gets trotted out periodically when they are running out of fud - a 'chewing the fud' so to speak - and are waiting/hoping for new material to show up.
Talking to yourself, again?
Does anyone know who is the "his source" that Bigger is talking about?
I got one too. Ignoring it.
I believe Sept 25 is the deadline for the MAA submission to be in the December CHM meeting. And September 26 is a Tuesday - the perfect time for an MAA submission PR.😁 Finally, aren't the defendants' responses to the plaintiff's last filing for the MTD due on September 27?
Yes, it did. Past emails addressed me by my first name. So, someone changed the database field used in the mail merge. 😆
There could have been a variety of reasons why they kept SOC for this trial and we will not know until the full story comes out. Unfortunately, that gives an opening for fudsters extraordinaire. The new trials being run at UCLA do not use SOC and preliminarily indicate far superior results. So, could be a case of baby steps in introducing and advancing a new therapy for a deadly condition.
Or additional combo trials with funding.
The L trial data has been locked, analyzed, reported in a prestigious journal, and is the basis of an MAA. So, yes, it is old news and the newer trials are the ones to focus on for new data and improvements in cancer treatment by DCVAX-L.
Now if DCVax-L does receive MHRA approval, what will your message be then? That it’ll never receive FDA approval?
Flipper has some of the best and insightful posts on the science of DCVAX-L as well as provided the best and consistent counters to fud about the science and regs from ex, lc, ic, poirman, etc.
Love the 'New 52 Week Low Today' banner that is steadily displayed at the top of the NVCR page on CNBC.
Brazen-ly lying.
LC walked into that one.
I think you missed this:
However, in glioblastoma, apart from the correlation of progression-free survival and overall survival from temozolomides effect, no surrogate endpoint is proven to strongly correlate with overall survival.31 As Phase III trials commonly use overall survival as the primary endpoint, encouraging Phase II data with surrogate endpoints have the potential for false signals. Further, opposing surrogate endpoints is that, for glioblastoma, precisely determining true response and progression is challenging.
Resistance is Futile.
Wow, the TOS have been really loosened since 'dog shit' and personal name calling is now allowed in posts.
I second Flipper's call to restore the TOS to pre-July 2023. At least some semblance of civility was maintained under those rules and reading the board didn't feel like stepping into a war zone every day.
The perennial Enron FUDding. Every time I think the fudsters have abandoned this line of attack, some desperate FUDder trots it out again.
With all the trials being run by Merck and BMY, that so far have failed, it looks like they are desperately trying to find an alternative and avoid having to pay NWBO.
could get hot long term.
You have repeatedly posted that RAs will see issues and find big holes and take a negative view of DCVAX-L and the trial, as well that the many knowledgeable posters on this board do not see these issues that RAs will raise. Since you are so confident of how the RAs will blow this up, how do you know this? Are you now or have you been an RA? If you have been one, then how long ago, as all fields of knowledge advance and evolve, as we have seen during the course of this trial.
A NewCo in the UK, while a complicated move, would put a stop to a lot of the troubles. They can still trade via ADRs on US exchanges.
It us their expectation it will be approved. No guarantees.
Many thanks, Flipper.
What were the CHM dates? I know they were posted on this board but as a free account holder I cannot search for them. Thanks.
Maverick_1 had identified a fourth 'female phenom', his term, who was part of a finance/investment team. Perhaps, a group put together by her is behind this, especially as MHRA submission/acceptance is expected to be announced soon?
Next week is the second week of June and Judge had opined that June flowers may appear then.
This is an excellent example of why all the bellyaching on this board about NWBO management's incompetence and delays is so unwarranted. We do not know all that is going on behind the scenes, especially with the regulators and NWBO cannot talk about all these developments for various legitimate reasons, including protecting the company from those who would rather see it fold.
Looks like there are multiple rows of ducks - all operable solid tumors?
NVCR pledges $3 million to conquer cancer at ASCO the other day.
Is tizsue agnostic a designation that the FDA formally bestows on a therapy?
Let's be very specific in our terminology. I believe it DCVAX was not alleged to be any fruit juice but very specifically, grapefruit juice.
An LA Times columnist recycles old material to cast NWBO in a negative light and The Street recycles a 2014 column from Adam F that mainly uses Risks and Disclaimers in a 10K while slapping an alarmist headline on May 9, 2023.
Looks like someone is running a bashing campaign but does not have any new material or cannot be explicitly associated with it as they may have been told to lie low.
I wonder if someone encouraged Hiltzim to slightly edit and republish his old article?
Curious statement when the title of her 10 minutes is Northwest Biotherapeutics.
And then she is participating in another session on Sunday discussing Immunological approaches, which most certainly have to include her work with ATL-DC vaccines, aka DCVAX-L and its successor improvements.
Says the survey with a sample size of 1.